Intercept's fatty liver drug meets late-stage main goal, shares soar
Intercept Pharmaceuticals Inc said on Tuesday its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ, taking the drug a step closer to approval and sending the company's shares surging 25 percent.
from Reuters: Health News https://reut.rs/2SK6V4B
http://bit.ly/2zwRqiM